Company profile: Maze Therapeutics
1.1 - Company Overview
Company description
- Provider of precision medicines for renal, cardiovascular, and metabolic diseases, including MZE829, an oral candidate for APOL1 kidney disease that mimics protective genetic variants, and MZE001, an oral substrate reduction therapy for Pompe disease. Offers the Compass platform integrating variant functionalization into drug development and genetic medicine programs for chronic kidney and cardio-metabolic diseases.
Products and services
- Compass Platform: Integrated platform embedding variant functionalization into drug development, advancing a pipeline of precision medicines for renal, cardiovascular, and metabolic diseases
- MZE829 for APOL1 Kidney Disease: Precision-targeted, oral product engineered to protect kidneys by mimicking protective APOL1 genetic variants, addressing APOL1 kidney disease
- MZE001 for Pompe Disease: Substrate-specific, oral therapy in development that reduces glycogen accumulation, applying substrate reduction to treat Pompe Disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Maze Therapeutics
C2i Genomics
HQ: United States
Website
- Description: Provider of cloud-based cancer diagnostic services for pharmaceutical and diagnostic organizations, offering the C2-Intelligence Platform that leverages whole-genome sequencing and AI to detect minimal residual disease, low-input liquid biopsy, and services for MRD-guided adjuvant treatment, organ preservation decisions, treatment response monitoring, and early recurrence detection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C2i Genomics company profile →
NorthGene
HQ: United Kingdom
Website
- Description: Provider of medical testing, health care and other services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NorthGene company profile →
Vector BioMed
HQ: United States
Website
- Description: Provider of state-of-the-art custom vector design and GMP manufacturing, specializing in Lentiviral vector production for research, pre-clinical, IND-enabling, and clinical trials using a serum-free, chemically-defined process; algorithm-based vector design optimized for titer, transduction, and transgene expression; custom assay development; and support services for clinical development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vector BioMed company profile →
Biomodal
HQ: United Kingdom
Website
- Description: Provider of DNA sequencing tools and multiomic solutions enabling combined genetic and epigenetic analysis from low-input DNA, distinguishing 5mC and 5hmC via duet multiomics solution evoC and +modC, which integrates assay and software for use with existing NGS pipelines; and modality, an analysis package for efficient, scalable 5- and 6-base genome analysis to inform genome organization and gene regulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomodal company profile →
Epimeron
HQ: United States
Website
- Description: Provider of gene discovery, deployment, and optimization solutions that support important plant biochemical functions required for maximum product yield.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epimeron company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Maze Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Maze Therapeutics
2.2 - Growth funds investing in similar companies to Maze Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Maze Therapeutics
4.2 - Public trading comparable groups for Maze Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →